(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 24.67% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Ironwood Pharmaceuticals's revenue in 2026 is $389,316,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $79,485,371,705, with the lowest IRWD revenue forecast at $75,559,270,565, and the highest IRWD revenue forecast at $82,586,925,511. On average, 6 Wall Street analysts forecast IRWD's revenue for 2027 to be $84,581,371,671, with the lowest IRWD revenue forecast at $79,655,568,851, and the highest IRWD revenue forecast at $88,138,987,730.
In 2028, IRWD is forecast to generate $131,661,537,370 in revenue, with the lowest revenue forecast at $81,615,314,622 and the highest revenue forecast at $229,518,286,383.